CA2936338A1 - (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders - Google Patents

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders Download PDF

Info

Publication number
CA2936338A1
CA2936338A1 CA2936338A CA2936338A CA2936338A1 CA 2936338 A1 CA2936338 A1 CA 2936338A1 CA 2936338 A CA2936338 A CA 2936338A CA 2936338 A CA2936338 A CA 2936338A CA 2936338 A1 CA2936338 A1 CA 2936338A1
Authority
CA
Canada
Prior art keywords
compound
mmol
piperidin
alkyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2936338A
Other languages
English (en)
French (fr)
Inventor
Lorin A. Thompson, Iii
John E. Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2936338A1 publication Critical patent/CA2936338A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA2936338A 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders Abandoned CA2936338A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925405P 2014-01-09 2014-01-09
US61/925,405 2014-01-09
PCT/US2015/010552 WO2015105929A1 (en) 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Publications (1)

Publication Number Publication Date
CA2936338A1 true CA2936338A1 (en) 2015-07-16

Family

ID=52444626

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936338A Abandoned CA2936338A1 (en) 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Country Status (27)

Country Link
US (10) US9187506B2 (https=)
EP (2) EP3092223B1 (https=)
JP (1) JP6629738B2 (https=)
KR (1) KR102331120B1 (https=)
AR (1) AR102019A1 (https=)
AU (1) AU2015204785A1 (https=)
CA (1) CA2936338A1 (https=)
CL (1) CL2016001744A1 (https=)
CY (1) CY1122768T1 (https=)
DK (1) DK3092223T3 (https=)
EA (1) EA201691133A1 (https=)
ES (1) ES2771825T3 (https=)
HR (1) HRP20200161T1 (https=)
HU (1) HUE048750T2 (https=)
IL (1) IL246596A0 (https=)
LT (1) LT3092223T (https=)
MX (1) MX2016008715A (https=)
PE (1) PE20160898A1 (https=)
PL (1) PL3092223T3 (https=)
PT (1) PT3092223T (https=)
RS (1) RS59858B1 (https=)
SG (1) SG11201605620QA (https=)
SI (1) SI3092223T1 (https=)
SM (1) SMT202000094T1 (https=)
TW (1) TW201612169A (https=)
UY (1) UY35946A (https=)
WO (1) WO2015105929A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
ES2822830T3 (es) 2015-10-14 2021-05-05 Bristol Myers Squibb Co Antagonistas selectivos de NR2B
JP6938485B2 (ja) * 2015-10-14 2021-09-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 選択的ｎｒ２ｂアンタゴニスト
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks
WO2024197289A1 (en) * 2023-03-22 2024-09-26 Gilgamesh Pharmaceuticals, Inc. Negative allosteric modulators of glun2b receptors and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
EA200200952A1 (ru) 2000-04-26 2003-02-27 Уорнер-Ламберт Компани Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
DE602004015610D1 (de) 2003-06-04 2008-09-18 Merck & Co Inc 3-fluoro-piperidine als nmda/nr2b antagonisten
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
EP2231655B1 (en) * 2007-11-13 2011-08-31 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
JP6629738B2 (ja) 2020-01-15
MX2016008715A (es) 2016-09-06
US20200297742A1 (en) 2020-09-24
DK3092223T3 (da) 2020-03-16
HUE048750T2 (hu) 2020-08-28
TW201612169A (en) 2016-04-01
PL3092223T3 (pl) 2020-05-18
SI3092223T1 (sl) 2020-02-28
US20170216325A1 (en) 2017-08-03
US9187506B2 (en) 2015-11-17
KR20160101194A (ko) 2016-08-24
KR102331120B1 (ko) 2021-11-24
US20180250316A1 (en) 2018-09-06
LT3092223T (lt) 2020-02-25
SMT202000094T1 (it) 2020-03-13
US20170065573A1 (en) 2017-03-09
PE20160898A1 (es) 2016-09-10
WO2015105929A1 (en) 2015-07-16
EA201691133A1 (ru) 2017-05-31
RS59858B1 (sr) 2020-02-28
EP3092223A1 (en) 2016-11-16
PT3092223T (pt) 2020-02-19
CN105873915A (zh) 2016-08-17
US20190125770A1 (en) 2019-05-02
AU2015204785A1 (en) 2016-08-25
US20150191496A1 (en) 2015-07-09
EP3092223B1 (en) 2019-12-11
JP2017503804A (ja) 2017-02-02
IL246596A0 (en) 2016-08-31
HRP20200161T1 (hr) 2020-05-01
EP3677578A1 (en) 2020-07-08
CL2016001744A1 (es) 2017-03-17
US20180104265A1 (en) 2018-04-19
US20190314392A1 (en) 2019-10-17
UY35946A (es) 2015-07-31
US20170340653A1 (en) 2017-11-30
AR102019A1 (es) 2017-02-01
US20160030456A1 (en) 2016-02-04
SG11201605620QA (en) 2016-08-30
ES2771825T3 (es) 2020-07-07
CY1122768T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
JP7787812B2 (ja) 置換大環状化合物および関連する治療方法
US20200297742A1 (en) (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
US9221796B2 (en) Selective NR2B antagonists
KR20100072077A (ko) 치환된 ｎ­페닐­비피롤리딘 카복스아미드 및 이의 치료적 용도
KR101682889B1 (ko) 치환된 테트라하이드로피란 스피로 피롤리디논 및 피페리디논, 이의 제조방법 및 이의 치료 용도
CN105873915B (zh) 用于治疗精神病症的化合物

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831